Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer-20 Years Later, and the Answer Is Still Yes
JAMA Netw Open
.
2021 Jul 1;4(7):e2117159.
doi: 10.1001/jamanetworkopen.2021.17159.
Authors
Samuel U Takvorian
1
,
Naomi B Haas
1
Affiliation
1
Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
PMID:
34292339
PMCID:
PMC9073645
DOI:
10.1001/jamanetworkopen.2021.17159
No abstract available
Publication types
Comment
MeSH terms
Bone Density Conservation Agents* / therapeutic use
Humans
Male
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Substances
Bone Density Conservation Agents
Grants and funding
K12 CA076931/CA/NCI NIH HHS/United States